STOCK TITAN

Xencor to Participate at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

PASADENA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at multiple upcoming investor conferences:

  • 2025 Wells Fargo Healthcare Conference
    Date: Wednesday, September 3, 2025
    Presentation Time: 3:00 p.m. ET / 12:00 p.m. PT
  • Cantor Global Healthcare Conference 2025
    Date: Thursday, September 4, 2025
    Presentation Time: 8:00 a.m. ET / 5:00 a.m. PT

Live webcasts of the presentations will be available under “Events & Presentations” in the Investors section of the Company’s website located at www.xencor.com. Replays of the events will be available on the Xencor website for at least 30 days following the presentations.

About Xencor

Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and multiple XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein’s structure that result in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.

Charles Liles

cliles@xencor.com

(626) 737-8118

Source: Xencor, Inc.

Xencor

NASDAQ:XNCR

XNCR Rankings

XNCR Latest News

XNCR Latest SEC Filings

XNCR Stock Data

572.01M
70.39M
1.23%
114.68%
12.97%
Biotechnology
Pharmaceutical Preparations
Link
United States
PASADENA